Transgene Biotek Limited (TRABI.BO)

INR 7.34

(-0.53%)

Long Term Debt Summary of Transgene Biotek Limited

Transgene Biotek Limited's latest annual long term debt in 2023 was 50.79 Million INR , up 2.61% from previous year.
Transgene Biotek Limited's latest quarterly long term debt in 2023 FY was 50.79 Million INR , up 2.61% from previous quarter.
Transgene Biotek Limited reported annual long term debt of 49.5 Million INR in 2022, up 3.8% from previous year.
Transgene Biotek Limited reported annual long term debt of 47.68 Million INR in 2021, up 4.99% from previous year.
Transgene Biotek Limited reported quarterly long term debt of 50.14 Million INR for 2023 Q2, down 0.0% from previous quarter.
Transgene Biotek Limited reported quarterly long term debt of 50.79 Million INR for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Transgene Biotek Limited (2023 - 2006)

Historical Annual Long Term Debt of Transgene Biotek Limited (2023 - 2006)

Year	Long Term Debt	Long Term Debt Growth
2023	50.79 Million INR	2.61%
2022	49.5 Million INR	3.8%
2021	47.68 Million INR	4.99%
2020	45.42 Million INR	6.23%
2019	42.75 Million INR	4.41%
2018	40.95 Million INR	6.52%
2017	38.44 Million INR	-25.9%
2016	51.89 Million INR	9.02%
2015	47.59 Million INR	-24.05%
2014	62.66 Million INR	5.64%
2013	59.32 Million INR	0.0%
2012	59.32 Million INR	-7.16%
2011	63.89 Million INR	-13.15%
2010	73.57 Million INR	-51.0%
2009	150.13 Million INR	10.69%
2008	135.63 Million INR	-25.16%
2007	181.25 Million INR	37.37%
2006	131.94 Million INR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2023 FY	50.79 Million INR	2.61%
2023 Q2	50.14 Million INR	0.0%
2023 Q4	50.79 Million INR	0.0%
2023 Q3	- INR	-100.0%
2023 Q1	- INR	-100.0%
2022 Q4	49.5 Million INR	0.0%
2022 FY	49.5 Million INR	3.8%
2022 Q1	- INR	-100.0%
2022 Q2	48.59 Million INR	0.0%
2022 Q3	- INR	-100.0%
2021 Q4	47.68 Million INR	0.0%
2021 Q2	46.55 Million INR	0.0%
2021 FY	47.68 Million INR	4.99%
2021 Q1	- INR	-100.0%
2021 Q3	- INR	-100.0%
2020 FY	45.42 Million INR	6.23%
2020 Q1	- INR	-100.0%
2020 Q3	- INR	-100.0%
2020 Q2	44.09 Million INR	0.0%
2020 Q4	45.42 Million INR	0.0%
2019 Q3	- INR	-100.0%
2019 FY	42.75 Million INR	4.41%
2019 Q2	41.25 Million INR	0.0%
2019 Q4	42.75 Million INR	0.0%
2018 FY	40.95 Million INR	6.52%
2018 Q1	- INR	0.0%
2018 Q4	40.95 Million INR	0.0%
2017 FY	38.44 Million INR	-25.9%
2016 FY	51.89 Million INR	9.02%
2015 FY	47.59 Million INR	-24.05%
2014 FY	62.66 Million INR	5.64%
2013 FY	59.32 Million INR	0.0%
2012 FY	59.32 Million INR	-7.16%
2012 Q1	66.34 Million INR	0.0%
2012 Q2	131.58 Million INR	98.32%
2012 Q4	59.32 Million INR	-54.92%
2012 Q3	131.58 Million INR	0.0%
2011 FY	63.89 Million INR	-13.15%
2010 FY	73.57 Million INR	-51.0%
2009 FY	150.13 Million INR	10.69%
2008 FY	135.63 Million INR	-25.16%
2007 FY	181.25 Million INR	37.37%
2006 FY	131.94 Million INR	0.0%

Peer Long Term Debt Comparison of Transgene Biotek Limited

Name	Long Term Debt	Long Term Debt Difference
Alfavision Overseas (India) Limited	1.35 Billion INR	96.255%
Biocon Limited	129.32 Billion INR	99.961%
Blue Jet Healthcare Limited	3.79 Million INR	-1240.237%
Concord Biotech Limited	18.87 Million INR	-169.184%
Dishman Carbogen Amcis Limited	2.45 Billion INR	97.932%
FERMENTA BIOTECH LIMITED	425.36 Million INR	88.058%
GENOMIC VALLEY BIOTECH LIMITED	- INR	-Infinity%
Lyka Labs Limited	429.06 Million INR	88.162%
Panacea Biotec Limited	209.9 Million INR	75.8%
SAMSRITA LABS LIMITED	- INR	-Infinity%
Servoteach Industries Limited	5059.00 INR	-1003952.184%
SMS Lifesciences India Limited	331.45 Million INR	84.675%
Supriya Lifescience Limited	50.2 Million INR	-1.185%
Syngene International Limited	1 Billion INR	94.921%
TAKE Solutions Limited	7.5 Million INR	-577.267%
Titan Biotech Limited	4.53 Million INR	-1020.56%
Vanta Bioscience Limited	488.01 Million INR	89.591%